Manulife (Manufacturers Life Insurance)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.22M	Buy	118,961 +33,391	+39%	+$553K	﹤0.01%	1460
2025 Q4	$1.13M	Buy	85,570 +20,314	+31%	+$240K	﹤0.01%	1785
2025 Q3	$468K	Sell	65,256 -44,713	-41%	-$2.33M	﹤0.01%	2241
2025 Q2	$5.19M	Sell	109,969 -14,935	-12%	-$608K	﹤0.01%	1151
2025 Q1	$4.88M	Sell	124,904 -17,798	-12%	-$767K	﹤0.01%	1173
2024 Q4	$7.73M	Buy	142,702 +24,576	+21%	+$1.25M	0.01%	1010
2024 Q3	$5.96M	Buy	118,126 +3,892	+3%	+$182K	0.01%	1135
2024 Q2	$5.02M	Buy	114,234 +31,401	+38%	+$1.33M	﹤0.01%	1163
2024 Q1	$4.16M	Sell	82,833 -1,088	-1%	-$59K	﹤0.01%	1267
2023 Q4	$5.07M	Buy	83,921 +10,210	+14%	+$526K	﹤0.01%	1166
2023 Q3	$4.2M	Buy	73,711 +10,974	+17%	+$606K	﹤0.01%	1192
2023 Q2	$3.2M	Buy	62,737 +14,187	+29%	+$382K	﹤0.01%	1272
2023 Q1	$1.04M	Buy	+48,550	New	+$816K	﹤0.01%	1618

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s MLTX Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its MoonLake Immunotherapeutics (MLTX) stake by 39% in Q1 2026, buying an estimated $553K and bringing the position to 118,961 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1460.

Manulife (Manufacturers Life Insurance) first reported a position in MLTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $7.73M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Manulife (Manufacturers Life Insurance) held 118,961 shares of MoonLake Immunotherapeutics worth $2.22M as of Q1 2026.
Manulife (Manufacturers Life Insurance) bought 33,391 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $553K.
MoonLake Immunotherapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1460 holding.
Manulife (Manufacturers Life Insurance) first reported a position in MoonLake Immunotherapeutics in Q1 2023 and has held it in 13 quarters since.
Manulife (Manufacturers Life Insurance)'s MoonLake Immunotherapeutics position peaked at $7.73M in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.